Experimental drug from Emory could see immediate use in India COVID surge

April 27, 2021

Access to an experimental COVID-19 drug invented by Emory University researchers is being made immediately available to India as the country faces a new, catastrophic wave of infections.



Antios Therapeutics Raises $96 Million in a Series B Financing

April 12, 2021

Funding will support the Phase 2 clinical program of ATI-2173 in HBV

Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain Associates and Sixty Degree Capital


Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B.


Emory, collaborators testing antiviral drug as potential treatment for coronaviruses

February 3, 2020

An antiviral compound discovered at Emory University could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.





Georgia Bio honors Emory drug innovator with Georgia Bio Community Award

January 30th, 2017

Georgia Bio has honored Abel De La Rosa, PhD, chief scientific officer of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD) with a 2017 Community Award.


NPR’s Closer look examines DRIVE and EIDD

04/02/2016

David Perryman of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development discusses the institute and how it ranks nationwide.